|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/25/20 Aclaris Therapeutics, Inc. 10-K 12/31/19 103:13M Toppan Merrill Bridge/FA |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 1.65M
2: EX-4.2 Instrument Defining the Rights of Security Holders HTML 44K
3: EX-10.14 Material Contract HTML 34K
4: EX-10.15 Material Contract HTML 34K
5: EX-10.20 Material Contract HTML 108K
6: EX-21.1 Subsidiaries List HTML 29K
7: EX-23.1 Consent of Experts or Counsel HTML 28K
8: EX-31.1 Certification -- §302 - SOA'02 HTML 33K
9: EX-31.2 Certification -- §302 - SOA'02 HTML 32K
10: EX-32.1 Certification -- §906 - SOA'02 HTML 33K
56: R1 Document and Entity Information HTML 64K
90: R2 Consolidated Balance Sheets HTML 131K
80: R3 Consolidated Balance Sheets (Parenthetical) HTML 46K
22: R4 Consolidated Statements of Operations and HTML 99K
Comprehensive Loss
57: R5 Consolidated Statements of Operations and HTML 30K
Comprehensive Loss (Parenthetical)
91: R6 Consolidated Statements of Stockholders' Equity HTML 89K
81: R7 Consolidated Statements of Stockholders' Equity HTML 33K
(Parenthetical)
23: R8 Consolidated Statements of Cash Flows HTML 133K
55: R9 Organization and Nature of Business HTML 41K
64: R10 Summary of Significant Accounting Policies HTML 112K
95: R11 Rhofade HTML 43K
39: R12 Fair Value of Financial Assets and Liabilities HTML 221K
28: R13 Property and Equipment, Net HTML 61K
65: R14 Intangible Assets HTML 82K
96: R15 Accrued Expenses HTML 49K
40: R16 Debt HTML 32K
29: R17 Stockholders' Equity HTML 38K
66: R18 Stock-Based Awards HTML 220K
94: R19 Net Loss per Share HTML 74K
59: R20 Leases HTML 142K
24: R21 Income Taxes HTML 185K
78: R22 Related Party Transactions HTML 40K
87: R23 Agreements Related to Intellectual Property HTML 52K
60: R24 Retirement Savings Plan HTML 32K
25: R25 Restructuring Charges HTML 32K
79: R26 Discontinued Operations HTML 190K
88: R27 Segment Information HTML 172K
58: R28 Legal Proceedings HTML 43K
26: R29 Summary of Significant Accounting Policies HTML 178K
(Policies)
32: R30 Rhofade (Tables) HTML 37K
42: R31 Fair Value of Financial Assets and Liabilities HTML 218K
(Tables)
93: R32 Property and Equipment, Net (Tables) HTML 60K
62: R33 Intangible Assets (Tables) HTML 83K
31: R34 Accrued Expenses (Tables) HTML 49K
41: R35 Stock-Based Awards (Tables) HTML 218K
92: R36 Net Loss per Share (Tables) HTML 75K
61: R37 Leases (Tables) HTML 140K
30: R38 Income Taxes (Tables) HTML 179K
43: R39 Discontinued Operations (Tables) HTML 192K
19: R40 Segment Information (Tables) HTML 170K
51: R41 Organization and Nature of Business (Details) HTML 33K
86: R42 Summary of Significant Accounting Policies HTML 51K
(Details)
77: R43 Summary of Significant Accounting Policies - HTML 36K
Property and Equipment (Details)
18: R44 Summary of Significant Accounting Policies - HTML 31K
Intangible Assets (Details)
50: R45 Summary of Significant Accounting Policies - HTML 35K
Goodwill (Details)
85: R46 Summary of Significant Accounting Policies - HTML 29K
Stock-Based Compensation (Details)
76: R47 Summary of Significant Accounting Policies - HTML 29K
Segments (Details)
17: R48 Summary of Significant Accounting Policies - HTML 34K
Recent Pronouncements (Details)
52: R49 RHOFADE - Amount Paid for Assets Acquired HTML 43K
(Details)
45: R50 RHOFADE - Summary of Fair Value Assets Acquired HTML 42K
(Details)
33: R51 Fair Value of Financial Assets and Liabilities HTML 66K
(Details)
71: R52 Fair Value of Financial Assets and Liabilities - HTML 49K
By Type (Details)
102: R53 Property and Equipment, Net (Details) HTML 53K
46: R54 Intangible Assets (Details) HTML 47K
34: R55 Intangible Assets - Future Amortization Expenses HTML 50K
(Details)
72: R56 Accrued Expenses (Details) HTML 41K
103: R57 Debt (Details) HTML 48K
44: R58 Stockholders' Equity (Details) HTML 41K
35: R59 Stockholders' Equity - Other Offerings (Details) HTML 55K
73: R60 Stock-Based Awards (Details) HTML 73K
83: R61 Stock-Based Awards - Option Activity (Details) HTML 89K
53: R62 Stock-Based Awards - RSUs (Details) HTML 54K
20: R63 Stock-Based Awards - Compensation (Details) HTML 50K
74: R64 Net Loss per Share (Details) HTML 38K
84: R65 Net Loss per Share - Anti-dilution (Details) HTML 36K
54: R66 Leases - Lease Costs (Details) HTML 37K
21: R67 Leases (Details) HTML 70K
75: R68 Leases - Finance Leases (Details) HTML 53K
82: R69 Leases - Supplemental Information Related to HTML 48K
Operating and Finance Leases (Details)
99: R70 Leases - Future Maturities of Lease Liabilities HTML 56K
(Details)
69: R71 Income Taxes - Tax Cuts and Jobs Act (Details) HTML 42K
37: R72 Income Taxes - Rate Reconciliation (Details) HTML 74K
48: R73 Income Taxes - Deferred Assets and Liabilities, HTML 89K
CFDs (Details)
98: R74 Income Taxes - Valuation Allowance and HTML 49K
Unrecognized Tax Benefits (Details)
68: R75 Related Party Transactions (Details) HTML 50K
36: R76 Agreements Related to Intellectual Property HTML 121K
(Details)
47: R77 Retirement Savings Plan (Details) HTML 33K
101: R78 Restructuring Charges (Details) HTML 49K
67: R79 Discontinued Operations - Loss (Details) HTML 67K
100: R80 Discontinued Operations - Assets and Liabilities HTML 83K
(Details)
70: R81 Discontinued Operations - Cash Flow (Details) HTML 44K
38: R82 Discontinued Operations (Details) HTML 38K
49: R83 Segment Information (Details) HTML 68K
97: R84 Legal Proceedings (Details) HTML 29K
89: XML IDEA XML File -- Filing Summary XML 181K
63: EXCEL IDEA Workbook of Financial Reports XLSX 116K
11: EX-101.INS XBRL Instance -- acrs-20191231 XML 3.40M
13: EX-101.CAL XBRL Calculations -- acrs-20191231_cal XML 261K
14: EX-101.DEF XBRL Definitions -- acrs-20191231_def XML 718K
15: EX-101.LAB XBRL Labels -- acrs-20191231_lab XML 1.80M
16: EX-101.PRE XBRL Presentations -- acrs-20191231_pre XML 1.22M
12: EX-101.SCH XBRL Schema -- acrs-20191231 XSD 218K
27: ZIP XBRL Zipped Folder -- 0001558370-20-001325-xbrl Zip 244K
| acrs_Ex21_1 |
Exhibit 21.1
Subsidiaries of Aclaris Therapeutics, Inc.
|
|
|
|
|
Name of Subsidiary |
|
Jurisdiction of Incorporation or |
|
|
|
|
|
Aclaris Therapeutics International Limited |
|
United Kingdom |
|
Aclaris Life Sciences, Inc. |
|
Delaware |
|
Confluence Discovery Technologies, Inc. |
|
Delaware |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/25/21 Aclaris Therapeutics, Inc. 10-K 12/31/20 104:12M Toppan Merrill Bridge/FA 1/20/21 Aclaris Therapeutics, Inc. 424B5 1:650K Toppan Merrill/FA 1/19/21 Aclaris Therapeutics, Inc. 424B5 1:652K Toppan Merrill/FA 8/13/20 Aclaris Therapeutics, Inc. 424B5 1:495K Toppan Merrill/FA |